1-1 of 1
Lynette Keyes-Elstein
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial: Metabolic and Immunologic Features at Baseline Identify a Subgroup of Responders

Kevan C. Herold, Stephen E. Gitelman, Mario R. Ehlers, Peter A. Gottlieb, Carla J. Greenbaum, William Hagopian, Karen D. Boyle, Lynette Keyes-Elstein, Sudeepta Aggarwal, Deborah Phippard, Peter H. Sayre, James McNamara, Jeffrey A. Bluestone, and the AbATE Study Team
Journal: Diabetes
Diabetes 2013;62(11):3766–3774
https://doi.org/10.2337/db13-0345
Published: 18 October 2013
View article titled, Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial: <subtitle>Metabolic and Immunologic Features at Baseline Identify a Subgroup of Responders</subtitle>
Open the PDF for Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial: <subtitle>Metabolic and Immunologic Features at Baseline Identify a Subgroup of Responders</subtitle> in another window
Includes: Supplementary data